Which pharmaceutical distribution company won the Ministry of Commerce, Industry and Energy’s national component technology development project? < Distribution < Pharmaceutical/Distribution < Text of article

[의학신문·일간보사=김상일 기자]Dongwon I-Pharm is attracting attention for being the first in the pharmaceutical distribution industry to win a national project from the Ministry of Commerce, Industry and Energy.

Dongwon I-Pharm (CEO Hyun Jun-jae) was finally selected as the lead company for the detailed project of the ‘2023 Materials and Components Technology Development Project’ supported by the Ministry of Trade, Industry and Energy and hosted by the Korea Evaluation Institute of Industrial Technology and Management, and is pursuing the development of a Korean-style cold chain integrated management platform. revealed.

The development project is a national project with a total investment of 15 billion won over 4 years and 6 months starting this year. The first sub-task is “Vacuum insulation material and integrated sensor module technology development for vaccine cold chain,” and the second sub-task is “mRNA vaccine distribution Korean-style cold chain.” Chain core materials, component forms, and application technology development”, and the third detailed task “mRNA vaccine ultra-low temperature storage, carrier performance verification, and verification test system development” will be carried out.

Dongwon I-Pharm is a research and development company in charge of the second sub-project and plans to develop an IoT-based Korean-style cold chain full-cycle integrated management platform through cooperative development of ultra-low temperature frozen and refrigerated cold chain medicine distribution parts and equipment, including mRNA vaccines between consortium companies. Dongwon Healthcare also plans to participate as a joint development company in the three detailed tasks.

The Catholic University Industry-Academic Cooperation Foundation (Professor Yang Dae-hyuk), Konkuk University Industry-Academic Cooperation Foundation (Professor Choi Myeong-seok), Korea Institute of Construction and Living Environment, Korea Institute of Industrial Technology, Seoul St. Mary’s Hospital and private companies formed a consortium to host and joint research and development institute. together with

Dongwon I-Pharm is an affiliate of Dongwon Pharmaceutical Group and specializes in distributing vaccines, medicines, and medical devices, including the National Immunization Project (NIP), based on a nationwide distribution network.

As an executing company for the government’s COVID-19 vaccine distribution project in 2021, it has been responsible for establishing a customized cold chain management system for each vaccine, including the ultra-low temperature Pfizer vaccine, and for nationwide distribution.

Hyun Jun-jae, CEO of Dongwon I-Pharm, said, “Recently, the cold chain pharmaceutical market has been growing rapidly, and since the introduction of the COVID-19 vaccine, the importance of cold chain distribution management, including ultra-low temperature frozen distribution such as mRNA vaccines, has been highlighted,” and “We have started this national project.” “We plan to strengthen our distribution capabilities for various cold chain medicines and expand the establishment of an integrated pharmaceutical cold chain distribution infrastructure with various market entities, including pharmaceutical companies.”

Meanwhile